Goldman Sachs initiates coverage on COAG: Buy, target price $36, positive on the Hemlibra-like potential of its bleeding-disorders pipeline

Overview

This report is Goldman Sachs' initiation of coverage on Hemab Therapeutics Holdings (COAG.US). The company is a clinical-stage biotech focused on treatments for hematologic coagulation disorders, with core assets including sutacimig (HMB-001) and HMB-002. The report believes sutacimig is positioned to establish an advantage in Glanzmann thrombasthenia (GT) and Factor VII deficiency (FVIID), while HMB-002 has the potential to penetrate the large von Willebrand Disease (VWD) market.

Core views

The core investment thesis has two parts: first, sutacimig may succeed in GT and FVIID because there is currently a lack of long-term subcutaneous prophylactic therapies, and early GT data have already shown a significant reduction in ATBR; second, HMB-002 may deliver competitive efficacy and dosing characteristics in VWD, with its mechanism indirectly supported by DDAVP and changes in VWF/FVIII biomarkers. Goldman Sachs' Buy rating is also supported by potential M&A value, orphan-disease market pricing power, and key readouts from late 2026 to early 2027.

Analysis framework

The report uses a combination of asset-by-asset clinical analysis, indication market-size estimation, risk-adjusted revenue forecasting, DCF valuation, and theoretical M&A valuation. In the valuation, 70% weighting comes from DCF, assuming a WACC of 16% and a terminal growth rate of 2%; 30% weighting comes from theoretical M&A valuation, using an 11x sales multiple applied to risk-adjusted 2033E forecasts.

Methodology notes

• Valuation methodsDCF/M&A weighted valuation

  70% DCF and 30% theoretical M&A valuation weighting

  The $36 target price is derived from a weighted average of DCF value of $30 and theoretical M&A value of $48; the M&A weighting reflects COAG being rated M&A Rank 1, corresponding to a relatively high probability of a potential acquisition.

• clinical developmentrisk-adjusted peak sales model

  modeling the value of core assets by indication and probability of success

  The report separately models the commercial potential of sutacimig in GT/FVIID and HMB-002 in VWD Type 1/Type 2, distinguishing between non-risk-adjusted and risk-adjusted peak sales.

• market analysisorphan-disease and large-indication market assessment

  assessing market potential by combining patient population, treatment gaps, route of administration, and comparable drug revenues

  GT/FVIID is centered on orphan-disease patient populations in the United States and GCC, while VWD references Hemlibra's revenue scale in subcutaneous prophylactic treatment for hemophilia A to assess the upper-end potential of HMB-002.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• sutacimig (HMB-001)

  COAG's core clinical asset, being developed as a subcutaneous prophylactic treatment for GT and FVIID.

  Strengths

  GT Ph.1/2 data showed up to an 87% reduction in ATBR; its mechanism enhances hemostatic activity by binding endogenous FVIIIa/FVIIa and TLT-1 on activated platelets; there is currently a lack of long-term subcutaneous prophylactic therapies.

  Weaknesses

  There are not yet direct clinical efficacy data in FVIID; GT Ph.3 design still needs alignment with the FDA; early sample sizes are limited.

  Comparison

  Compared with existing on-demand treatments such as rFVIIa or platelet transfusion, sutacimig aims to provide a long-acting subcutaneous prophylactic option.

  Risks

  Key risks include thromboembolic events, elevated D-dimer, the impact of ADA on PK/PD, and fluctuations in real-world bleeding rates.

• HMB-002

  COAG's second clinical-stage asset, intended for subcutaneous prophylactic treatment of VWD.

  Strengths

  Its mechanism is designed to increase endogenous VWF and Factor VIII; in the single-dose 20mg and 50mg cohorts, VWF and Factor VIII were observed to rise more than 1.5x from baseline and remain elevated for at least 8 to 10 days.

  Weaknesses

  There are currently no formal clinical efficacy data; validation will require higher doses, repeat dosing, and data from longer treatment durations.

  Comparison

  The report compares its potential to Hemlibra's commercial success in subcutaneous prophylactic treatment for hemophilia A and views VGA039 as the main competing asset.

  Risks

  Risks include failure of biomarker increases to translate into meaningful reductions in ABR/ATBR, safety being inferior to standard treatments or competitors, and faster progress by competing products such as VGA039.

• Hemab Therapeutics Holdings (COAG.US)

  A clinical-stage hematology platform company whose valuation is mainly driven by sutacimig, HMB-002, and its early pipeline.

  Strengths

  It has two clinical-stage assets, multiple near-term data catalysts, and has been included by Goldman Sachs in M&A Rank 1.

  Weaknesses

  The company remains pre-commercial, and its value is highly dependent on clinical success and financing capability.

  Comparison

  The report values it using Goldman Sachs' biotech coverage M&A framework and DCF framework.

  Risks

  If the core assets fail or the competitive landscape deteriorates, the report's downside scenario valuation is $14 and does not include M&A value.

Key data

• rating and target priceBUY; 12-month target price $36.00Current price $25.89, implying 39.0% upside.
• market capitalization and enterprise valueMarket cap $1.2bn; Enterprise value $885.7mnKey data disclosed on the front page of the report.
• sutacimig peak salesabout $1.3B non-risk-adjusted peak sales; about $700M risk-adjusted salesCovers the two indications GT and FVIID.
• HMB-002 peak salesabout $3B non-risk-adjusted peak salesA subcutaneous prophylactic treatment opportunity for VWD Type 1 and Type 2.
• early efficacy of sutacimigup to 87% reduction in ATBR in GT Ph.1/2The 0.3mg/kg weekly dose has performed best in the data so far.
• valuation assumptionsWACC 16%; TGR 2%; DCF $30; theoretical M&A $48; weighted target price $36DCF weighting 70%, theoretical M&A weighting 30%.
• near-term catalysts2H26 to early 2027Including GT Ph.3 initiation, FVIID Ph.2 proof-of-concept data, and preliminary multidose data from VWD Ph.1/2.

Impact & implications

If sutacimig continues to show efficacy with manageable safety in GT Ph.3 and FVIID Ph.2, COAG could gain a first-mover advantage in the rare bleeding-disorder market where subcutaneous prophylactic therapies are lacking. If HMB-002 demonstrates that biomarker increases in VWD can translate into actual reductions in bleeding rates, the company's value could expand from an orphan-disease platform into a larger indication market. Conversely, if the early clinical assets fail to show meaningful efficacy or encounter safety issues, downside valuation risk would be significant.

Risks

• sutacimig delivers lower-than-expected efficacy in GT Ph.3 or FVIID Ph.2.
• sutacimig shows significant thromboembolic risk or other safety issues.
• HMB-002 fails to demonstrate in VWD that increases in VWF/FVIII can translate into meaningful reductions in bleeding rates.
• HMB-002 lacks advantages versus standard treatments or competing assets such as VGA039 in efficacy, safety, or dosing convenience.
• FDA communication, trial design, enrollment criteria, or sample-size limitations lead to delays in key data or make interpretation more difficult.
• As a pre-commercial biotech company, COAG faces risks related to financing, R&D execution, and realization of its early pipeline.

What to watch

• In 2H26, the timing, dose selection, and enrollment criteria for initiation of the sutacimig Ph.3 study in GT.
• Proof-of-concept data for sutacimig in FVIID Ph.2 in late 2026 or early 2027.
• Preliminary data from the multidose portion of the HMB-002 VWD Ph.1/2 Velora Pioneer study in late 2026 or early 2027.
• How well thromboembolic risk, D-dimer, ADA, and patient risk factors are controlled in follow-up studies of sutacimig.
• Differences between HMB-002 and VGA039 in ABR/ATBR reduction, applicable VWD subtypes, enrollment restrictions, and dosing convenience.
• Progress of COAG's early preclinical assets entering clinical development in 2H26 and initial clinical data in mid-2027.